WASHINGTON (January 22, 2025) — The Board of Directors of the Association for Accessible Medicines has reelected as Chair for a second one-year term, Keren Haruvi, President, Sandoz North America. The Board also reconfirmed for a second term Bob Hoffman, Chief Commercial Officer of US Generics for Lupin Pharmaceuticals, Inc. as Vice Chair of the Board, and Jeff Burd, President & CEO, North America, Ajanta Pharma USA Inc. as Treasurer.

“It has been an honor to lead our AAM board and I’m excited to continue as chair,” said Keren Haruvi, President of Sandoz North America. “Together, we will work to foster predicable and sustainable access to high quality generic and biosimilar medicines for America’s patients; and focus on educating and working with our regulators, legislators, and the administration on the real threats facing our industry. I look forward to working with fellow board members and the AAM team to shine a light on the life-changing, positive impact of generic and biosimilar medicines.”

Prior to her current role at Sandoz, Haruvi served as Global Head of M&A for Novartis after 14 years at Teva Pharmaceuticals.

John Murphy III, President and CEO of AAM, stated, “Keren’s leadership has been invaluable, and we are thankful she will serve a second term in this role. With stable and consistent Board Officers, AAM will continue to protect the sustainability of our industry and help ensure lower-cost, vital generic and biosimilar medicines are always available to patients and hospitals.”

 

MEDIA CONTACT:

For media inquiries, contact the Communications Department at media@accessiblemeds.org.

 

About AAM

The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 13.1 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at biosimilarscouncil.org.